Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) fell ~12% in the premarket on Friday after the company announced data from its US and UK-conducted first-in-human dose escalation clinical study of ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall readout is in line with the Chinese data that drummed up excitement in the ...

Corbus Pharmaceuticals has a 12 month low of $6.54 and a 12 month high of $61.90. The stock’s fifty day moving average price is $9.98 and its 200-day moving average price is $20.82.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private ...

Corbus Pharmaceuticals on Friday presented new data from the first Western study of its antibody-drug conjugate treatment for cancer that largely mirrored previous results reported from China ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP advanced 1.03% to $6.84 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite ...

In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $65.00. The company’s ...

Shares of Corbus Pharmaceuticals Holdings Inc. CRBP shed 2.58% to $6.79 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index ...

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...

(RTTNews) - Corbus Pharmaceuticals Holdings, Inc.(CRBP), has reported promising data for CRB-701 or SYS6002, a next-generation Nectin-4 targeting antibody-drug conjugate or ADC, at the 2025 ...

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval ...